ResearcherFirst Affiliated Hospital Zhejiang UniversityNo recent work listed

Bingfeng Huang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111870838. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper

Papers 2

Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, rand… Co-author DOI 10.1186/s12885-022-09974-7 ↗
Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. Co-author PMID 30788003 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tingbo Liang · 2 shared papers, 2019–2022 · strength 0.23
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7 ↗
- Paper Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. PMID 30788003 ↗
Tao Ma · 1 shared paper, 2022 · strength 0.14
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7 ↗
Qichun Wei · 1 shared paper, 2022 · strength 0.14
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7 ↗
Risheng Que · 1 shared paper, 2022 · strength 0.14
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7 ↗
Mengyi Lao · 1 shared paper, 2022 · strength 0.14
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7 ↗
Wei Chen · 1 shared paper, 2022 · strength 0.14
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7 ↗
Xueli Bai · 1 shared paper, 2022 · strength 0.14
- Paper Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage I… DOI 10.1186/s12885-022-09974-7 ↗
Jianxin Wang · 1 shared paper, 2019 · strength 0.09
- Paper Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. PMID 30788003 ↗
Jian Zhang · 1 shared paper, 2019 · strength 0.09
- Paper Gemcitabine enhances OSI-027 cytotoxicity by upregulation of miR-663a in pancreatic ductal adenocarcinoma cells. PMID 30788003 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.